Security
Alector, Inc. Common Stock · ALEC
ALECNASDAQCommon stockCurrentCIK 1653087Updated Oct 6, 2026
Name history
Alector LLC · through Sep 16, 2015
ALEC price & chart
Loading TradingView…
NASDAQ:ALEC on TradingView ↗About the company
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
In the news
Biotech Brainiacs and Breakthroughs ↗
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint News provided by Levi & Korsinsky, LLP Jan 29, 2026, 18:06 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Levi & ↗
Seeking Alpha
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript ↗
Alector surges on licensing agreement with Genentech ↗
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
SEC disclosures
Alector, Inc. files 8-K: Material Event ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 1.01, 2.02, 7.01, 8.01, 9.01
144 filing
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 293,237,000Source | 468,303,000Source | 621,827,000Source | 787,648,000Source |
| Property, Plant and Equipment, NetUSD | 10,841,000Source | 17,145,000Source | 21,861,000Source | 25,521,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 65,802,000Source | 33,021,000Source | 74,555,000Source | 154,323,000Source |
| Assets, CurrentUSD | 266,452,000Source | 424,817,000Source | 565,807,000Source | 726,435,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,428,000Source | 11,420,000Source | 16,946,000Source | 10,997,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,712,000Source | 19,951,000Source | 25,195,000Source | 27,811,000Source |
| Other Assets, NoncurrentUSD | 386,000Source | 4,544,000Source | 7,418,000Source | 6,409,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 262,588,000Source | 341,503,000Source | 487,669,000Source | 573,206,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 11,000Source | 9,000Source | 8,000Source | 8,000Source |
| Additional Paid in CapitalUSD | 1,002,528,000Source | 955,657,000Source | 844,044,000Source | 798,696,000Source |
| Retained Earnings (Accumulated Deficit)USD | -972,056,000Source | -829,127,000Source | -710,078,000Source | -579,687,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 166,000Source | 261,000Source | 184,000Source | -4,575,000Source |
| Stockholders' Equity Attributable to ParentUSD | 30,649,000Source | 126,800,000Source | 134,158,000Source | 214,442,000Source |
| Liabilities and EquityUSD | 293,237,000Source | 468,303,000Source | 621,827,000Source | 787,648,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 69,503,000Source | 125,059,000Source | 177,948,000Source | 93,809,000Source |
| Operating Lease, Liability, CurrentUSD | 9,056,000Source | 8,754,000Source | 8,462,000Source | 8,059,000Source |
| Accounts Payable, CurrentUSD | 1,691,000Source | 2,215,000Source | 3,775,000Source | 4,189,000Source |
| Operating Lease, Liability, NoncurrentUSD | 17,488,000Source | 24,376,000Source | 30,456,000Source | 35,268,000Source |
| Other Liabilities, NoncurrentUSD | 1,737,000Source | 1,234,000Source | 1,373,000Source | 759,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 19,299,000Source | 28,890,000Source | 30,378,000Source | 27,771,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,323,000Source | 9,389,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 26,658,000Source | 39,463,000Source | 42,798,000Source | 46,146,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -524,000Source | -1,441,000Source | -377,000Source | -572,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -184,031,000Source | -229,905,000Source | -184,162,000Source | -20,329,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 196,597,000Source | 107,131,000Source | 101,918,000Source | -159,014,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 41,000Source | 1,255,000Source | 2,381,000Source | 4,117,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,215,000Source | 81,540,000Source | 2,550,000Source | 4,514,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 32,781,000Source | -41,234,000Source | -79,694,000Source | -174,829,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 67,648,000Source | 34,867,000Source | 76,101,000Source | 155,795,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 855,000Source | — | — | — |
| Income Taxes Paid, NetUSD | -880,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 26,658,000Source | 39,463,000Source | 42,798,000Source | 46,146,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 293,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | 0Source | -48,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 53,987,000Source | 59,615,000Source | 56,687,000Source | 61,033,000Source |
| Income Tax Expense (Benefit)USD | 168,000Source | 128,000Source | 5,212,000Source | 3,254,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Operating ExpensesUSD | 177,052,000Source | 245,555,000Source | 248,802,000Source | 271,451,000Source |
| Operating Lease, Impairment LossUSD | 2,922,000Source | 2,205,000Source | — | 0Source |
| Other Nonoperating Income (Expense)USD | 13,246,000Source | 26,076,000Source | 26,561,000Source | 7,778,000Source |
| Proceeds from Issuance of Common StockUSD | 19,983,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 15,000Source | 0Source | 1,079,000Source | 3,059,000Source |
| Restructuring CostsUSD | 7,300,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 21,045,000Source | 100,558,000Source | 97,062,000Source | 133,617,000Source |
| Operating Income (Loss)USD | -156,007,000Source | -144,997,000Source | -151,740,000Source | -137,834,000Source |
| Other Nonoperating Income (Expense)USD | 13,246,000Source | 26,076,000Source | 26,561,000Source | 7,778,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -142,761,000Source | -118,900,000Source | — | — |
| Income Tax Expense (Benefit)USD | 168,000Source | 128,000Source | 5,212,000Source | 3,254,000Source |
| Net Income (Loss) Attributable to ParentUSD | -142,929,000Source | -119,049,000Source | -130,391,000Source | -133,310,000Source |
| Earnings Per Share, BasicUSD per share | -1.39Source | -1.23Source | -1.56Source | -1.62Source |
| Earnings Per Share, DilutedUSD per share | -1.39Source | -1.23Source | -1.56Source | -1.62Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 102,998,978Source | 96,588,177Source | 83,733,730Source | 82,467,587Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 102,998,978Source | 96,588,177Source | 83,733,730Source | 82,467,587Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 5,718,000Source | 5,407,000Source | 5,725,000Source | 5,714,000Source |
| General and Administrative ExpenseUSD | 53,987,000Source | 59,615,000Source | 56,687,000Source | 61,033,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -142,761,000Source | -118,921,000Source | -125,179,000Source | -130,056,000Source |
| Labor and Related ExpenseUSD | 51,783,000Source | 73,200,000Source | — | — |
| Operating ExpensesUSD | 177,052,000Source | 245,555,000Source | 248,802,000Source | 271,451,000Source |
| Research and Development ExpenseUSD | 123,065,000Source | 185,940,000Source | 192,115,000Source | 210,418,000Source |
| Restructuring CostsUSD | 7,300,000Source | — | — | — |
Filing attachments
alec-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enz…
Read attachment ↗alec-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 alec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alector Reports First Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for A…
Read attachment ↗